Supplementary Materials

Supplementary Material for:

Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling

Juliann Chmielecki, Jasmine Foo, Geoffrey R. Oxnard, Katherine Hutchinson, Kadoaki Ohashi, Romel Somwar, Lu Wang, Katherine R. Amato, Maria Arcila, Martin L. Sos, Nicholas D. Socci, Agnes Viale, Elisa de Stanchina, Michelle S. Ginsberg, Roman K. Thomas, Mark G. Kris, Akira Inoue, Marc Ladanyi, Vincent A. Miller, Franziska Michor,* William Pao*

*To whom correspondence should be addressed. E-mail: michor{at}jimmy.harvard.edu (F.M.); william.pao{at}vanderbilt.edu (W.P.)

Published 6 July 2011, Sci. Transl. Med. 3, 90ra59 (2011)
DOI: 10.1126/scitranslmed.3002356

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Further characterization of PC-9 TKI-resistant cell lines.
  • Fig. S2. Characterization of EGFR-mutant TKI-resistant cells.
  • Fig. S3. Characterization of H3255 TKI-resistant cells.
  • Fig. S4. Rate of progression in T790M-harboring EGFR-mutant lung cancer.
  • Fig. S5. Derivation of mathematical parameters.
  • Fig. S6. Continuation of TKI therapy in cell populations with T790M-harboring clones leads to better tumor cell control.
  • Fig. S7. Toxicity of "gatekeeper" mutations in other cell models.
  • References

[Download PDF]